

UnitedHealthcare Pharmacy
Clinical Pharmacy Programs

Program Number	2026 P 1471-2
Program	Prior Authorization/Notification
Medication	Crenessity™ (crinecerfont) oral capsule and oral suspension
P&T Approval Date	2/2025, 2/2026
Effective Date	5/1/2026

1. Background:

Crenessity (crinecerfont) is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).

2. Coverage Criteria^a:

A. Initial Authorization

1. **Crenessity** will be approved based upon **all** of the following criteria:

a. Diagnosis of *classic* congenital adrenal hyperplasia (CAH)

-AND-

b. Patient is 4 years of age or older

-AND-

c. Patient will receive concomitant glucocorticoid replacement (e.g., dexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)

Authorization will be issued for 12 months.

B. Reauthorization

1. **Crenessity** will be approved based upon **both** of the following criteria:

a. Documentation of positive clinical response to Crenessity therapy

-AND-

b. Patient will continue to receive concomitant glucocorticoid replacement (e.g., dexamethasone, hydrocortisone, methylprednisolone, prednisone, prednisolone)

Authorization will be issued for 12 months.

^aState mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

3. Additional Clinical Rules:

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.
- Supply limits may be in place.

4. Reference:

1. Crenessity [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; December 2024.

Program	Prior Authorization/Notification - Crenessity (crinecerfont)
Change Control	
2/2025	New program
2/2026	Annual review with no changes.